Clive Ballard, MD

July 30, 2021

Clive Ballard, MD, spoke on the safety data of pimavanserin, which was presented at the 2021 AAIC meeting, held from July 26-30.

July 29, 2021

Clive Ballard, MD, professor of age related diseases at University of Exeter, commented on the potential impact that the approval of pimavanserin would have for patients if approved for dementia-related psychosis.

July 28, 2021

Clive Ballard, MD, spoke on safety data presented at this year’s AAIC meeting, as well as the impact of symptoms associated with DRP, which can be distressing for individuals and their families.

July 27, 2021

Ballard, a professor of age related diseases at University of Exeter, discussed the results from a recent trial of pimavanserin in dementia-related psychosis, and data presented at this year’s AAIC meeting.

July 01, 2021

Clive Ballard, MD, discussed up-and-coming technologies for remote risk assessment, among other data presented at this year’s AAIC meeting.

May 02, 2021

The dean at the University of Exeter Medical School discussed ongoing studies of pimavanserin and his thoughts on the FDA’s actions related to the agent.

April 20, 2021

The dean at the University of Exeter Medical School discussed the questions related to treating dementia-related psychosis and the options available.

July 17, 2019

The professor of age-related diseases and Dean of the University of Exeter Medical School spoke about the need for proper training of nursing home staff in order to improve quality of life in patients with dementia.

July 23, 2018

Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.